Date of presentation: April 21, 2013
Laboratory research involving samples of triple-negative breast cancer cells found that exposure to low-dose aspirin slowed the growth of the cells. These results were presented at the 2013 annual meeting of the American Society for Biochemistry and Molecular Biology, held in conjunction with the Experimental Biology Conference 2013.
Aspirin has a wide range of effects in the body, and its potential for beneficial effects against cancer has interested researchers for many years. Results thus far are most promising for colorectal cancers.
To explore the effects of aspirin against breast cancer cells in the laboratory, researchers treated two different breast cancer cells lines, one of which was triple-negative.
Aspirin slowed the growth of the cancer cells-including the triple-negative cells-and also reduced tumor growth in mice.
This study does not mean that women with triple-negative breast cancer should begin taking aspirin. The study did not evaluate aspirin in humans with cancer, and aspirin has important risks such as gastrointestinal bleeding. Research in this area, however, is likely to continue.